U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07239336) titled 'Phase II Study of DONQ52 in Active Celiac Disease' on Nov. 16.
Brief Summary: The main aim is to see how DONQ52 works to improve small intestinal damage and reduce celiac-related symptoms due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.
Study Start Date: Dec. 15
Study Type: INTERVENTIONAL
Condition:
Celiac Disease
Intervention:
DRUG: Placebo DONQ52
Placebo DONQ52 subcutaneous injection
DIETARY_SUPPLEMENT: Simulated Inadvertent Gluten Exposure (SIGE) capsule
SIGE gluten capsules orally
DRUG: DONQ52
DONQ52 subcu...